Pulmatrix, Inc.

Equities

PULM

US74584P3010

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-25 pm EDT			5-day change	1st Jan Change
2.08 ^USD	+2.97%		+6.12%	+11.83%

Mar. 28	Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 13	Pulmatrix, Inc. Approves Termination of Margaret Wasilewski as Chief Medical Officer	CI

PULMATRIX : Other Events, Financial Statements and Exhibits (form 8-K/A)

April 13, 2021 at 04:11 pm EDT

Item 8.01. Other Events.

The Company issued a corrected press release regarding the termination of the License, Development and Commercialization Agreement by and between Johnson & Johnson Enterprise Innovation, Inc. and the Company on April 12, 2021, which is attached hereto as Exhibit 99.1. The original press release incorrectly noted that the Company plans to initiate a PUR1800 Phase 2 proof-of-concept efficacy study for the treatment of AECOPD in 2021. This study is not expected to commence until 2022.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits



Exhibit
Number    Description

 99.1       Press Release dated April 12, 2021

Latest news about Pulmatrix, Inc.

Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Pulmatrix, Inc. Approves Termination of Margaret Wasilewski as Chief Medical Officer	Mar. 13	CI
Pulmatrix Explores Strategic Alternatives	Jan. 08	CI
Pulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternatives	Jan. 08	DJ
Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis	Jan. 08	CI
Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.8M	Nov. 09	MT
Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole	23-08-23	CI
Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Earnings Flash (PULM) PULMATRIX Reports Q2 Revenue $1.8M	23-08-10	MT
Sector Update: Health Care Stocks Easing Late Tuesday	23-07-11	MT
Sector Update: Health Care Stocks Lower Tuesday Afternoon	23-07-11	MT
Pulmatrix Seeks FDA Approval to Launch Phase 2 Trial of Investigational Drug for Acute Migraine Treatment; Shares Rise	23-07-11	MT
Pulmatrix, Inc. Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine	23-07-11	CI
Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Earnings Flash (PULM) PULMATRIX Reports Q1 Revenue $1.5M	23-05-12	MT
Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Pulmatrix Doses First Patient in Phase 2b Asthma Trial	23-02-06	MT
Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis in Subjects with Asthma	23-02-06	CI
Pulmatrix Reports Top-Line Results From Acute Migraine Treatment	23-01-04	MT
Pulmatrix, Inc. Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine, for Acute Migraine	23-01-04	CI
Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.9M	22-11-10	MT
Pulmatrix Completes Patient Dosing for Phase 1 Study of Acute Migraine Drug Candidate	22-09-26	MT
Pulmatrix, Inc. Announces Patient Dosing Completed for Its Novel Inhaled Therapy PUR3100 for Acute Migraine	22-09-26	CI

Chart Pulmatrix, Inc.

Duration

Period

More charts

Company Profile

Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Companyâs proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Companyâs product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Companyâs therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
PULMATRIX, INC.	+11.83%	7.38M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	104B
REGENERON PHARMACEUTICALS, INC.	+1.41%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.84%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.63%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.98B
SAREPTA THERAPEUTICS, INC.	+32.11%	11.66B

Bio Therapeutic Drugs

Pulmatrix, Inc.

Equities

PULM

US74584P3010

Biotechnology & Medical Research

PULMATRIX : Other Events, Financial Statements and Exhibits (form 8-K/A)

Latest news about Pulmatrix, Inc.

Chart Pulmatrix, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs